Last €9.10 EUR
Change Today -0.202 / -2.17%
Volume 0.0
VQY On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:09 AM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

volcano corp (VQY) Snapshot

Open
€9.06
Previous Close
€9.30
Day High
€9.10
Day Low
€9.06
52 Week High
10/21/13 - €17.91
52 Week Low
09/10/14 - €8.91
Market Cap
468.2M
Average Volume 10 Days
127.0
EPS TTM
--
Shares Outstanding
51.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VOLCANO CORP (VQY)

volcano corp (VQY) Related Businessweek News

No Related Businessweek News Found

volcano corp (VQY) Details

Volcano Corporation designs, develops, manufactures, and commercializes a suite of precision guided therapy tools worldwide. The company operates in two segments, Medical and Industrial. It offers intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products that enhance the diagnosis and treatment of coronary and peripheral vascular disease by enhancing the efficiency and efficacy of existing diagnostic angiograms and percutaneous coronary interventional and endovascular procedures in the coronary arteries or peripheral arteries and veins. The company’s IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters; and ChromaFlo stent apposition analysis technology that uses sequential IVUS frames to differentiate circulating blood from stationary or anchored tissue. Its FFR products comprise pressure and flow consoles, and single-procedure disposable pressure and flow guide wires, which are used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque’s physiological impact on blood flow and pressure. In addition, the company offers adenosine-free Instant Wave-Free Ratio FFR; and SyncVision, which co-registers IVUS with angiography. Further, the company develops and manufactures optical monitors for the telecommunication industry; laser and non-laser light sources; optical engines used in the medical optical coherence topography imaging systems and advanced photonic components; and sub-systems used in spectroscopy and other industrial applications. It sells its products through direct sales force and distributors, as well as through supply and distribution agreements with third parties. Volcano Corporation was founded in 2000 and is headquartered in San Diego, California.

1,800 Employees
Last Reported Date: 02/28/14
Founded in 2000

volcano corp (VQY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $638.5K
Chief Finance Officer and Principal Accountin...
Total Annual Compensation: $381.3K
Executive Vice President of Strategy, Busines...
Total Annual Compensation: $358.0K
Compensation as of Fiscal Year 2013.

volcano corp (VQY) Key Developments

Volcano Seeks Acquisitions

Volcano Corporation (NasdaqGS:VOLC) seeks acquisitions. "From a growth standpoint, we feel very good about what we have in our ability to grow the 6% to 8% that we talked about and our focus is on doing that. Is there some small acquisition that I see us making in the next 12 to 24 months, maybe $50 million or less, yes, but that will be it. And again it would be a product that doesn't have regulatory risk, doesn't have development risk, and is either on the market or ready to go-to-market where there is not a bunch of additional spends and they can leverage our existing distribution networks. So we see minimal M&A for us here over the next 12 to 24 months. We're going to focus on executing on what we have," said, Scott Huennekens, Volcano Corporation - Chief Executive Officer.

Volcano Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 11:10 AM

Volcano Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 11:10 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: R. Scott Huennekens, Chief Executive Officer, President and Director.

Volcano Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and First Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full Year of 2014

Volcano Corporation reported unaudited consolidated earnings results for the second quarter and first six months ended June 30, 2014. For the quarter ended June 30, 2014, the company reported revenues of $102.6 million against revenues of $101.3 million in the same period a year ago. Foreign currency exchange rates did not have a material impact on revenues during the quarter. Medical segment revenues increased approximately 2% on a reported basis. The company reported net income on a GAAP basis of $282,000, or $0.01 per diluted share, in the second quarter of 2014, against a net loss of $2.4 million, or $0.04 per share, in the same period a year ago. The results for the second quarter of 2014 included an acquisition-related benefit of $7.2 million related to an adjustment to a contingent liability resulting in a net benefit of $6.4 million, while the results for the second quarter of 2013 included a gain on a strategic investment of $2.2 million. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported non-GAAP net income of $0.01 per diluted share, compared with non-GAAP earnings per diluted share of $0.03 in the second quarter a year ago. Operating income was $7.305 million against operating loss of $0.114 million a year ago. Income before income tax was $0.267 million against loss before income tax of $4.438 million a year ago. Non-GAAP net income was $0.534 million. For the first six months of 2014, the company reported revenues of $197.1 million against revenues of $194.6 million in the first six months of 2013. On a constant currency basis, revenues increased 3% year-over-year after adjusting for a negative impact of approximately $2.7 million from foreign currency. For the first six months of 2014, the company reported a net loss on a GAAP basis of $10.6 million, or $0.21 per share, against a net loss of $5.5 million, or $0.10 per share, in the same period a year ago. The results for the first six months of 2014 included a net acquisition-related benefit of $5.4 million, while the results for the first six months of 2013 included other income of $4.2 million. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP net loss of $0.10 per share in the first six months of 2014, compared with non-GAAP net earnings per diluted share of $0.06 in the first six months of 2013. Operating loss was $1.210 million against $1.902 million a year ago. Loss before income tax was $14.917 million against $11.313 million a year ago. Net cash used in operating activities was $1.941 million against net cash provided by operating activities of $1.527 million a year ago. Capital expenditures were $14.661 million against $18.490 million a year ago. Non-GAAP net loss was $5.336 million. The company provided updated guidance for the full year 2014. Based on current foreign currency exchange rates, it expects revenues on a reported basis will be $397.0-$401.0 million, with revenues on a constant currency basis in the range of $401.0-$405.0 million. The company said it expects gross margins will be in the range of 63.0-63.5% and that operating expenses, including restructuring charges, will be 65.5-66.5% of revenues. On a reported basis, the company expects a GAAP net loss of $0.52-$0.55 per share. The company is maintaining its prior guidance for a net loss per share of $0.16-$0.19 on a non-GAAP basis. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense, and assume an effective tax rate of 35.0% for the GAAP to non-GAAP adjustments. For the third quarter of 2014, the company expects revenues in the range of $95.0-$97.0 million on a reported and $95.5-$97.5 million constant currency basis. It expects gross margins will be in the range of 62.0-62.5% and that operating expenses will be in the range of 69.0-70.0% of revenues. The company expects a net loss per share of $0.17-$0.19 on a GAAP basis and $0.04-$0.06 on a non-GAAP basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VQY:GR €9.10 EUR -0.202

VQY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $24.67 USD -0.46
AtriCure Inc $15.12 USD -0.63
Cardiovascular Systems Inc $26.85 USD -0.46
Spectranetics Corp/The $28.01 USD -0.50
Vascular Solutions Inc $23.01 USD -0.35
View Industry Companies
 

Industry Analysis

VQY

Industry Average

Valuation VQY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLCANO CORP, please visit www.volcanocorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.